在此次获批之前，本公司的Geri胚胎培养液(Gems胚胎培养液系列产品之一)已分别取得欧洲合格认证 ("CE")、美国食品药品监督管理局(Food and Drug Administration)("FDA")认证及澳大利亚药品管理局 (Therapeutic Goods Administration)("TGA")认证。该产品之核心技术来源于悉尼体外受精中心。结合Geri 湿式时差培养箱与AI胚胎评估系统，Geri胚胎培养液已正式进入中国临床实践，以其抗氧化配方与稳定 渗透压环境的两大核心优势，解决了高龄患者胚胎培养的难题。 Geri胚胎培养液的技术核心在于针对高龄患者生育难点构建系统性解决方案。其"三重抗氧化防护网"能 有效应对高龄胚胎的氧化应激难题，配合提前添加人血清白蛋白与超长效期稳定性，大幅简化实验室操 作并确保培养环境稳定。国际临床验证显示，该培养液结合Geri湿式时差培养箱及AI胚胎评估系统，可 显着提升优质囊胚率与临床妊娠率，为高龄生育提供坚实保障。 贝康医疗-B(02170)发布公告，本公司的Geri胚胎培养液(Gems胚胎培养液系列产品之一)于2026年2月25 日获得中国国家药品监督管理 ...

Geri胚胎培养液的技术核心在于针对高龄患者生育难点构建系统性解决方案。其"三重抗氧化防护网"能 有效应对高龄胚胎的氧化应激难题，配合提前添加人血清白蛋白与超长效期稳定性，大幅简化实验室操 作并确保培养环境稳定。国际临床验证显示，该培养液结合Geri湿式时差培养箱及AI胚胎评估系统，可 显著提升优质囊胚率与临床妊娠率，为高龄生育提供坚实保障。 此次获批标志着公司实现从引进技术到本土化生产的关键跨越，填补国产高端辅助生殖耗材空白，成为 首个拥有FDA、CE、TGA、NMPA四大国际权威认证的中国企业。凭藉PGT核心技术及耗材自供能 力，公司已覆盖全国绝大部分PGT持牌机构，并设有数十家本地化实验室，形成持续迭代的生态壁垒。 格隆汇2月26日丨贝康医疗-B(02170.HK)公告，公司的Geri胚胎培养液(Gems胚胎培养液系列产品之一) 于2026年2月25日获得中国国家药品监督管理局("国家药监局")颁发的三类医疗器械注册证(注册证号： 国械注进20263180071)。 在此次获批前，公司的Geri胚胎培养液(Gems胚胎培养液系列产品之一)已分别取得欧洲合格认证 ("CE")、美国食品药品监督管理局(Fo ...

智通财经APP讯，贝康医疗-B(02170)发布公告，本公司的Geri胚胎培养液(Gems胚胎培养液系列产品之 一)于2026年2月25日获得中国国家药品监督管理局("国家药监局")颁发的三类医疗器械注册证(注册证 号：国械注进20263180071)。 在此次获批之前，本公司的Geri胚 胎 培 养 液(Gems胚胎培养液系列产品之一)已 分 别 取 得 欧 洲 合 格 认 证("CE")、美 国 食 品 药 品 监 督 管 理 局(Food and Drug Administration)("FDA")认 证 及 澳 大 利 亚 药 品 管 理 局(Therapeutic Goods Administration)("TGA")认证。该产品之核心技术来源于悉尼体外受精 中心。结合Geri湿式时差培养箱与AI胚胎评估系统，Geri胚胎培养液已正式进入中国临床实践，以其抗 氧化配方与稳定渗透压环境的两大核心优势，解决了高龄患者胚胎培养的难题。 Geri胚胎培养液的技术核心在于针对高龄患者生育难点构建系统性解决方案。其"三重抗氧化防护网"能 有效应对高龄胚胎的氧化应激难题，配合提前添加人血清白蛋白与超长效期稳定 ...

Suzhou Basecare Medical Corporation Limited 蘇 州 貝 康 醫 療 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2170） 自願公告 Geri胚胎培養液（Gems胚胎培養液系列產品之一） 獲國家藥監局頒發醫療器械註冊證 本公告由蘇州貝康醫療股份有限公司（「本公司」，連同其子公司統稱「本集團」） 自願刊發，以告知本公司股東及潛在投資者有關本集團業務的最新發展。 本公司董事會（「董事會」）欣然宣佈，本公司的Geri胚胎培養液（Gems胚胎培養 液系列產品之一）於2026年2月25日獲得中國國家藥品監督管理局（「國家藥監局」） 頒發的三類醫療器械註冊證（註冊證號：國械註進20263180071）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 此次獲批標誌著公司實現從引進技術到本土化生產的關鍵跨越，填補國產高 端輔助生殖耗材空白，成為首 ...

转自：中国科学报 在宝妈备孕社群里，"补充维生素D"是流传甚广的"经验之谈"。尤其对于多囊卵巢综合征（PCOS）的女 性，它常被视为辅助生殖路上的一个"加分项"。但这个辅助手段，真有用吗？近日，浙江大学医学院附 属妇产科医院在国际医学期刊《英国医学杂志》上发表论文，为这个备受关注的问题提供了迄今为止最 高级别的循证答案。 这项由浙大妇院张丹教授团队领衔，悉尼大学NHMRC临床试验中心王睿高级研究员团队、北京大学第 三医院李蓉教授团队等共同完成的研究发现，对于准备接受体外受精-胚胎移植辅助生殖技术（IVF- ET）的多囊女性，术前常规补充维生素D虽能显著提升血液中的维生素D水平，但并未显著提高最终的 活产率。 多囊备孕，补充维D能提高"命中率"吗 多囊卵巢综合征是育龄期女性最常见的内分泌及代谢紊乱性疾病之一，全球患病率约在5%至20%之 间，是导致女性无排卵性不孕的首要病因。当自然受孕困难、诱导排卵助孕无效时，体外受精-胚胎移 植是这些患者重要的解决方案。 在辅助生殖领域，每一个"可能有用"的建议都牵动着备孕家庭的心。维生素D就是一个经常被"cue"到 的"助孕帮手"。因为它不仅与骨骼健康紧密相关，其受体还广泛 ...

Core Viewpoint - The company, Canar Medical, is experiencing a decline in revenue and profit, with a significant reliance on overseas sales benefiting from the depreciation of the RMB [3][7]. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018 [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, while the average circulating shares per person increased by 2.13% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 13, Canar Medical's stock price fell by 0.06%, with a trading volume of 61.59 million yuan and a turnover rate of 2.52%, resulting in a total market capitalization of 3.911 billion yuan [1]. - The stock has seen a net inflow of 2.74 million yuan from major investors today, with a ranking of 19 out of 138 in its industry, although the industry overall has experienced a net outflow of 461 million yuan [4][5]. Group 4: Technical Analysis - The average trading cost of the stock is 28.95 yuan, with the stock price currently near a support level of 31.49 yuan, indicating potential for a rebound if this level holds [6].

Core Viewpoint - The company, Canar Medical, has seen a stock price increase of 3.14% with a trading volume of 140 million yuan and a market capitalization of 3.897 billion yuan, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction [1][2][3]. Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables. The main products include puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, with an average of 10,872 circulating shares per person, an increase of 2.13% [7]. Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 28.77 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak. The current stock price is near a support level of 31.49 yuan, which is critical for potential rebound or further decline [6].

Core Viewpoint - Wanfu Biological experienced a stock price increase of 12.81% year-to-date, with a notable rise of 4.11% in the last five trading days, indicating positive market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Wanfu Biological reported a revenue of 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders was 134 million yuan, down 69.32% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.213 billion yuan, with 601 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wanfu Biological was 42,400, a decrease of 5.59% from the previous period. The average number of circulating shares per shareholder increased by 5.94% to 10,160 shares [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.1927 million shares, a reduction of 1.3623 million shares from the previous period. The Southern Zhongzheng 1000 ETF held 2.6442 million shares, down by 20,900 shares [3]. Business Overview - Wanfu Biological, established on November 13, 1992, and listed on June 30, 2015, specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to point-of-care testing (POCT) [1]. - The company's revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other supplementary services (0.04%) [1]. Market Position - Wanfu Biological is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics. The company is associated with various concept sectors, including avian influenza drugs, assisted reproduction, anti-influenza, gene sequencing, and the pet economy [1].

Core Viewpoint - Tongce Medical's stock has shown a positive trend with a year-to-date increase of 12.41%, reflecting strong performance in the medical service sector [1][2]. Group 1: Stock Performance - As of January 21, Tongce Medical's stock price reached 45.20 CNY per share, with a market capitalization of 20.217 billion CNY [1]. - The stock has experienced a 4.15% increase over the last five trading days, a 10.19% increase over the last 20 days, and a 6.60% increase over the last 60 days [1]. - The company has seen a net outflow of 12.52 thousand CNY in principal funds, with significant buying and selling activity from large orders [1]. Group 2: Financial Performance - For the period from January to September 2025, Tongce Medical reported a revenue of 2.29 billion CNY, representing a year-on-year growth of 2.56%, and a net profit attributable to shareholders of 514 million CNY, up 3.06% year-on-year [2]. - The company has distributed a total of 392 million CNY in dividends since its A-share listing, with 340 million CNY distributed over the past three years [3]. Group 3: Shareholder Structure - As of January 10, the number of shareholders for Tongce Medical decreased to 90,000, while the average number of circulating shares per person increased by 8.89% to 4,969 shares [2]. - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with some shareholders reducing their holdings [3].

Market Overview - On January 19, Hong Kong stocks showed weak upward momentum, with the Hang Seng Index falling by 281 points (1.1%) to close at 26,563 points[1] - The Hang Seng Tech Index decreased by 72 points (1.2%), closing at 5,749 points, with total trading volume at HKD 225.7 billion[1] - Xiaomi, OPPO, vivo, and Transsion lowered their annual shipment forecasts, impacting stock prices, with Xiaomi (1810 HK) down 1.7% and Sunny Optical (2382 HK) down 2.3%[1] Sector Performance - The aviation sector strengthened, with Eastern Airlines (670 HK) and Southern Airlines (1055 HK) rising by 6%-9% due to expected record-high passenger transport during the Spring Festival[1] - The power equipment sector benefited from a planned investment of HKD 4 trillion by the State Grid during the 14th Five-Year Plan, with stocks like Dongfang Electric (1072 HK) and Harbin Electric (1133 HK) increasing by 5%-6%[1] Macroeconomic Insights - The GDP growth for Q4 2025 is projected at 4.5%, with an annual growth rate of 5.0%, meeting expectations[2] - Exports for 2025 are expected to increase by 5.5%, despite a 20% decline in exports to the U.S., showing resilience with an annual trade surplus of USD 1.2 trillion, a historical high[2] Real Estate Sector - Real estate development investment fell by 36.9% year-on-year to RMB 419.7 billion, a larger decline than November's 31.4%[3] - New housing starts decreased by 19.3% to 53.13 million square meters, while the average price index for new residential properties in 70 cities dropped by 3.0% year-on-year[3] Industry Developments - The automotive sector saw Chery Automobile (9973 HK) rise by 4.5% after announcing its AI strategy, marking a shift towards smart vehicles[4] - The renewable energy sector is encouraged to adopt zero-carbon practices, with companies like CIMC Enric (3899 HK) expected to benefit from new policies[4] Pharmaceutical Sector - Most pharmaceutical stocks declined alongside the Hang Seng Index, but leading reproductive health company Jinxin Fertility (1951 HK) rose by 5.3%[5] - The number of newborns is projected to drop from 9.54 million in 2024 to 7.92 million in 2025, prompting government support for childbirth[5]